Definium Therapeutics, Inc. (DFTX)
| Market Cap | 6.07B +706.2% |
| Revenue (ttm) | n/a |
| Net Income | -353.79M |
| EPS | -3.48 |
| Shares Out | 134.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,311,081 |
| Open | 45.85 |
| Previous Close | 46.14 |
| Day's Range | 43.51 - 45.96 |
| 52-Week Range | 8.70 - 49.70 |
| Beta | 2.26 |
| Analysts | Strong Buy |
| Price Target | 60.13 (+33.18%) |
| Earnings Date | Aug 6, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $60.13, which is an increase of 33.18% from the latest price.
News
Definium Therapeutics Earnings Call Transcript: Q2 2026
Phase III results for DT120 ODT in MDD showed unprecedented efficacy and tolerability, with pivotal GAD data imminent. Strong financials, including $1.1B in cash, support ongoing R&D and commercial launch preparations, positioning the company for long-term growth.
Definium Therapeutics Earnings release: Q2 2026
Definium Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Definium Therapeutics Quarterly report: Q2 2026
Definium Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)
of June 30, 2026, Definium Therapeutics (DFTX) had cash, cash equivalents and investments of approximately $1.1 billion compared to $411.6 million as of December 31, 2025. Based on the Company’s…
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics initiated with an Overweight at Wells Fargo
Wells Fargo analyst Benjamin Burnett initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and $68 price target The firm believes Spravato validates the interventional psychiatr...
Definium Therapeutics price target raised to $73 from $48 at Piper Sandler
Piper Sandler raised the firm’s price target on Definium Therapeutics (DFTX) to $73 from $48 and keeps an Overweight rating on the shares. The firm says its thinking is not…
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics announces results from healthcare claims study in GAD
Definium Therapeutics (DFTX) announced results from a new healthcare claims study of treatment patterns of newly diagnosed and established GAD patients, including pharmacotherapy use, discontinuation,...
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics price target raised to $60 from $30 at Stifel
Stifel raised the firm’s price target on Definium Therapeutics (DFTX) to $60 from $30 and keeps a Buy rating on the shares. Better-than-expected MDD data for DT120 has significantly de-risked…
Definium Therapeutics price target lowered to $58 from $60 at Canaccord
Canaccord lowered the firm’s price target on Definium Therapeutics (DFTX) to $58 from $60 and keeps a Buy rating on the shares. The firm noted the company recently reported stellar…
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major...
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly...
Definium Therapeutics rises 21.8%
Definium Therapeutics (DFTX) is up 21.8%, or $7.88 to $44.06.
Definium Therapeutics Stock (DFTX) Soars on a Public Offering Pricing After Strong Trial Results
Definium Therapeutics stock was up after the company priced a new $700 million public offering.
Definium Therapeutics rises 17.7%
Definium Therapeutics (DFTX) is up 17.7%, or $6.40 to $42.58.
Definium Therapeutics 20.6M share Secondary priced at $34.00
The deal size was increased to $700M in common stock from $500M in common stock. JPMorgan, Jefferies, Leerink and BofA acted as joint book running managers for the offering. Published…
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics, Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Transcript: Study result
The phase III EMERGE study of DT120 ODT in MDD demonstrated rapid, robust, and durable efficacy, with an 8.1-point placebo-adjusted MADRS improvement at week six and strong safety. Benefits were consistent across subgroups, and the open-label extension showed sustained response. Regulatory discussions are ongoing, with pivotal GAD readouts expected soon.
Definium Therapeutics Press release: Study result
Definium Therapeutics issued a press release on June 22, 2026, disclosing material business information to investors.